Please assess the completion status of the following clinical trial:

Trial Title: Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Is 19 to 70 (inclusive) years old at Visit 1 (Screening).~2. Is diagnosed with Type 2 Diabetes Mellitus with~   * HbA1c between 6.0 to 9.5% (inclusive) for subjects managing their diabetes with:~     i. Diet and exercise alone, or ii. A stable regimen (minimum of 2 months at Visit 1) of metformin alone, or iii. A stable regimen (minimum of 2 months at Visit 1) of DPP-4 inhibitor alone, OR~  * HbA1c between 6.0 to 8.5% (inclusive) for subjects managing their diabetes with a stable (minimum of 2 months at Visit 1) combination regimen of metformin and DPP-4 inhibitors.~3. Has serum creatinine below the upper limit of normal at Visit 1 and an estimated creatinine clearance above 80 using the Crockroft and Gault equation (CrCl = \[(140 - age) x body weight in kg\] / (serum creatinine x 72) x (0.85 for females) \[ref. 3\].~4. Has a body mass index (BMI) of 25.0 to 40.0 kg/m\^2 (inclusive) at Screening.~5. Is male, or is female and meets all of the following criteria:~   * Not breastfeeding~  * Negative pregnancy test result (human chorionic gonadotropin, beta subunit) at Visit 1 (Screening) (not applicable to hysterectomized females)~  * Surgically sterile, postmenopausal, or if of childbearing potential, must practice and be willing to continue to practice appropriate birth control during the entire duration of the study~6. Has a physical examination with no clinically significant abnormalities as judged by the investigator.~7. Ability to understand and willingness to adhere to protocol requirements.~8. If on chronic thyroid pharmacologic therapy, the dose must be stable for at least 3 months prior to Visit 1 (Screening), and must have thyroid-stimulating hormone (TSH) test result in normal range at Visit 1 (Screening).~Exclusion Criteria:~1. Has a clinically significant medical condition that could potentially affect study participation and/or personal well-being, as judged by the investigator, including but not limited to the following conditions:~   * Hepatic disease~  * Renal disease~  * Gastrointestinal disease~  * Endocrine disorder except diabetes~  * Cardiovascular disease~  * Seizure disorder~  * Organ transplantation~  * Chronic infection~2. Has any chronic disease requiring medication that has been adjusted in the past 90 days (subjects may take acute intermittent over-the-counter medications such as Tylenol, if needed).~3. Has any drug treatment that affects gastric pH (prescription or over-the-counter), including any antacids or medications such as Rolaids or Pepcid within 2 days of Visit 1 (Screening).~4. Has had major surgery of any kind within 6 months of Visit 1 (Screening).~5. Has received a blood transfusion within 6 months of Visit 1 (Screening).~6. Has a history of \>5 kg weight change within 3 months of Visit 1 (Screening).~7. Has clinical laboratory test (clinical chemistry, hematology, or urinalysis) abnormalities other than those expected in subjects with diabetes and judged by the investigator to be clinically significant at Visit 1 (Screening).~8. Has physical, psychological, or historical finding that, in the investigator's opinion, would make the subject unsuitable for the study.~9. Currently abuses drugs or alcohol or has a history of abuse that in the investigator's opinion would cause the individual to be noncompliant with study procedures.~10. Has donated blood within 2 months of Visit 1 (Screening) or is planning to donate blood during the study.~11. Has used insulin within 3 months of Visit 1 (Screening).~12. Has received GLP-1 receptor agonists and/or thiazolidinedione treatment within 6 months of Visit 1 (Screening).~13. Has known intolerance to metformin.~14. Has received any investigational drug within 1 month (or five half-lives of the investigational drug, whichever is greater) of Visit 1 (Screening).~15. Has known allergies or hypersensitivity to any component of study treatment.~16. Is employed by Elcelyx Therapeutics, Inc (that is an employee, temporary contract worker, or designee of the company).~17. Smokes more than 10 cigarettes per day, 2 cigars per day, or uses more than 1 can of smokeless tobacco per week.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1000 mg EFB0026 (metformin immediate-release) (Type: ACTIVE_COMPARATOR): BID
- 1000 mg EFB0027 (metformin delayed-release) (Type: EXPERIMENTAL): BID
- 500 mg EFB0027 (metformin delayed-release) (Type: EXPERIMENTAL): BID
- 500 mg EFB0026 + 1000 mg EFB0027 (Type: EXPERIMENTAL): BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete